Lilly To Acquire Versanis To Improve Patient Outcomes In Cardiometabolic Diseases

Jul 14, 2023•over 2 years ago

Acquiring Company

Eli Lilly

Acquired Company

Versanis

IndianapolisManufacturingHealth CareBiopharmaTherapeuticsBiotechnologyHealth Care

Description

Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.

Company Information

Company

Eli Lilly

Location

Indianapolis, Indiana, United States

About

Eli Lilly is a global healthcare and pharmaceutical company focused on the discovery, development, and delivery of innovative pharmaceutical medicines, vaccines, and consumer healthcare products. It has a strong presence in the diabetes and obesity market segment and has been actively expanding its manufacturing network to meet the increasing demand for its medicines.

Related People

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Lilly To Acquire Versanis To Improve Patient Outcomes In Cardiometabolic Diseases

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

M&A Insights

Company Information